🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSemaglutide (Ozempic / Wegovy)0.25mg → 2.4mg titration: optimal schedule based on clinical data

0.25mg → 2.4mg titration: optimal schedule based on clinical data

Dr.Martinez Sun, Jun 7, 2026 at 10:54 AM 6 replies 138 viewsPage 1 of 2
Dr.Martinez
Medical Advisor
3,891
28,456
Nov 2023
Boston, MA
Online
Jun 7, 2026 at 10:54 AM#1

Collecting this in one place because it comes up every few weeks and the answer is always assembled from scratch. It is about the titration schedule, and it is deliberately narrow — everything I am not confident about is marked as such.

What is actually established

Holding longer is the underrated move. A step that is uncomfortable at week two is frequently comfortable at week six with no change in dose, because the gastric-emptying component tachyphylaxes while the appetite effect persists. Escalating at week two throws that adaptation away.

The condition it depends on

One condition: holding indefinitely at a dose that is not doing anything is not patience, it is a stall with a nice name. The distinction is whether appetite has changed at all at the current step.

The practical version

The arithmetic in one line: half-life about a week, so steady state at four to five weeks, so a four-week interval is one steady state per step. Two-week intervals mean every step is dosed onto a rising curve.

What I am not sure about

What I am after is why the interval is four weeks rather than two, and whether a slower ladder gets to the same place. I have searched first, so if this is covered somewhere point me at it and I will read it.

— Dr.Martinez · corrections welcome and will be edited into this post with credit
46 16AttorneyGrant, DebRD_ATL, KristenIndy and 43 others
Reply Quote Save Share Report
NeuroNate
Senior Member
2,890
16,789
Dec 2023
Chicago, IL
Jun 7, 2026 at 11:16 AM#2
Dr.Martinez said:
A step that is uncomfortable at week two is frequently comfortable at week six with no change in dose, because the gastric-emptying component…

That is correct as far as it goes, and here is where it stops going. The trials generally allowed a step to be held or reduced and then retried, and people who did that mostly arrived at the same place a few weeks later. The end point of the ladder is set by tolerability, not by a schedule, and there is no evidence that reaching the top faster produces a better outcome.

45 15wendy_avl, jason_paloalto, Dr.LeslieOBGYN and 42 others
Reply Quote Save Share Report
Dr.RenalNash
VIP Member
1,234
7,890
Mar 2024
Nashville, TN
Jun 7, 2026 at 11:38 AM#3
Dr.Martinez said:
A step that is uncomfortable at week two is frequently comfortable at week six with no change in dose, because the gastric-emptying component…

I disagree that the ladder is purely tolerability. The maintenance and regain data cluster at the top doses, so a ladder abandoned halfway leaves you outside the evidence base for the part that matters most — keeping it off.

Last edited: Jun 7, 2026 at 4:38 PM
44 14Dr.NutriCornell, pam_stl, wei_SG and 41 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
anders_CPH
Senior Member
1,567
7,234
Feb 2024
Copenhagen, DK
Jun 7, 2026 at 12:00 PM#4

This one has a reasonably settled answer, so here it is. Four weeks is the pharmacokinetics, not caution. With a one-week half-life you need four to five half-lives to reach steady state, so at two weeks you are dosing on top of a concentration that has not finished rising. Escalating then stacks exposure and you get the side-effect burden of the higher dose before you have seen the benefit of the current one.

43 13BethLabQueen, ChrisMacros, KetoKyle and 40 others
Reply Quote Save Share Report
hank_denver
Member
278
1,234
Sep 2024
Denver, CO
Jun 7, 2026 at 2:01 PM#5
NeuroNate said:
The trials generally allowed a step to be held or reduced and then retried, and people who did that mostly arrived at the same place a few weeks…

Adding a me-too, because a thread of one person's experience is not much use. I had assumed I was the exception until I read this.

Last edited: Jun 7, 2026 at 6:01 PM
42 12Dr.DermMIA, fiona_VT, denise_HTX and 39 others
Reply Quote Save Share Report

Similar Threads

STEP 1-5 trials comprehensive summary — efficacy endpoints compiled12 replies
Oral semaglutide 50mg Phase 3 — OASIS program results16 replies
Semaglutide pharmacokinetics — half-life, Tmax, steady state modeling10 replies
Compounded semaglutide stability data — temperature and light sensitivity16 replies
Semaglutide and GFR improvement — FLOW trial renal endpoints15 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register